Cargando…
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C‐C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We evaluated the efficacy and safety of cenicriviroc...
Autores principales: | Eksteen, Bertus, Bowlus, Christopher L., Montano‐Loza, Aldo J., Lefebvre, Eric, Fischer, Laurent, Vig, Pamela, Martins, Eduardo Bruno, Ahmad, Jawad, Yimam, Kidist K., Pockros, Paul J., Feld, Jordan J., Minuk, Gerald, Levy, Cynthia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917279/ https://www.ncbi.nlm.nih.gov/pubmed/33681680 http://dx.doi.org/10.1002/hep4.1619 |
Ejemplares similares
-
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study
por: Bowlus, Christopher L., et al.
Publicado: (2023) -
The immunobiology of primary sclerosing cholangitis
por: Aron, Jonathan H., et al.
Publicado: (2009) -
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020) -
Prognostic Significance of Severe Vitamin D Deficiency in Patients with Primary Sclerosing Cholangitis
por: Ebadi, Maryam, et al.
Publicado: (2023) -
PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)
por: Stinton, Laura M., et al.
Publicado: (2014)